ハヤシ　モトヒロ   HAYASHI Motohiro   林　基弘    所属   医学部 医学科（東京女子医科大学病院）    職種   教授
論文種別	総説
言語種別	英語
査読の有無	査読なし
表題	Gamma Knife Radiosurgery for Pituitary Adenomas Invading the Cavernous Sinus: Tokyo Women's Medical University Experience
掲載誌名	正式名：Acta Neurochirurgica Supplement 略　 称：Acta Neurochir Suppl ISSNコード：0065-1419
掲載区分	国外
巻・号・頁	128,pp.29-41
著者・共著者	Hayashi Motohiro†*, Chernov Mikhail, Horiba Ayako, Tamura Noriko, Amano Kosaku, Kawamata Takakazu
担当区分	筆頭著者,責任著者
発行年月	2021
概要	Total surgical removal of a pituitary adenoma (PA) invading the cavernous sinus (CS) is challenging and carries a significant risk of postoperative complications. As an alternative treatment strategy, after incomplete resection, such tumors may undergo stereotactic radiosurgery-in particular, Gamma Knife surgery (GKS). Treatment planning based on advanced neuroimaging (e.g., thin-slice 3-dimensional postcontrast constructive interference in steady state (CISS) images) allows clear visualization of the target microanatomy, which results in highly conformal and selective radiation delivery to the lesion with preservation of adjacent functionally important neurovascular structures. In the Tokyo Women's Medical University experience of GKS for 43 nonfunctioning and 46 hormone-secreting PA invading the CS, with a minimum follow-up period of 5 years (mean 76 months, range 60-118 months), the tumor control rate has reached 97%, and a significant volume reduction (≥50%) has been seen in 24% of lesions. In cases of hormone-secreting neoplasms, normalization (in 18 patients; 39%) or improvement (in 22 patients; 48%) of endocrinological function has been noted. Importantly, such effects have been sufficiently durable. Complications have been extremely rare and limited to transient cranial nerve palsy (in 2% of cases). Notably, no patient in our series has had a new pituitary hormone deficit after irradiation. Thus, subtotal resection followed by GKS may be considered a valuable alternative to aggressive surgery for a PA invading the CS.
DOI	10.1007/978-3-030-69217-9_4
PMID	34191059